64th ASH Annual Meeting and Exposition: 731. Autologous Transplantation: Clinical and Epidemiological: Lymphoma, AML, and Multiple Sclerosis

Symposia: Autologous Transplantation: Clinical and Epidemiological Oral and Poster Abstracts
Oral

Research, clinical trials, Hodgkin lymphoma, Acute Myeloid Malignancies, AML, adult, autoimmune disorders, Biological therapies, Lymphomas, non-Hodgkin lymphoma, Clinical Practice (Health Services and Quality), Non-Biological therapies, epidemiology, Clinical Research, B Cell lymphoma, Plasma Cell Disorders, Chemotherapy, Combination therapy, health outcomes research, T Cell lymphoma, pediatric, Checkpoint Inhibitor, Diseases, Immune Disorders, patient-reported outcomes, real-world evidence, Therapies, clinical procedures, registries, Lymphoid Malignancies, young adult , Adverse Events, survivorship, Myeloid Malignancies, Technology and Procedures, Study Population, Human, Transplantation

220-222 (Ernest N. Morial Convention Center)

Moderators:

Joanna Zurko, MD, University of Wisconsin and Zohra Nooruddin, MD, Long School of Medicine, University of Texas Health San Antonio

Disclosures:

Nooruddin: Astrazeneca: Research Funding.

9:30 AM

487

Patient-Reported-Outcomes and Safety of Autologous Stem Cell Transplantation in Multiple Sclerosis: A Single Center Experience with the “Mexican Method” in 1300 Persons

Juan Carlos Olivares-Gazca, MD^1,2^*, Daniela Sánchez-Bonilla, MD^1,2^*, José Antonio Fernández-Gutiérrez, MD^1,2^*, Oscar A. Reyes-Cisneros, MD³^*, Moisés Manuel Gallardo-Pérez, MD^1,2^*, Guillermo José Ruiz-Delgado, MD, FACP¹^* and Guillermo José Ruiz-Argüelles, MD, FRCP (Glasg), MACP, DSc(hc), FRCP⁴

¹Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, Mexico
²Universidad Popular Autónoma del Estado de Puebla, Puebla, Mexico
³Universidad Anáhuac Puebla, Puebla, Mexico
⁴Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, PU, Mexico

9:45 AM

488

A Randomized Phase II Trial Comparing BeEAM with BEAM As Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma Patients

Felix Keil¹^*, Antonia Maria Susanne Müller^2,3^*, Andrea Berghold, Univ.Prof. DI Dr.⁴^*, Veronika Buxhofer-Ausch, MD⁵^*, Judith Schuster, Mag. Dr.⁶^*, Regina Riedl, DI Dr.⁴^*, Corinne Vorburger⁷^*, Alexandra Boehm, MD⁸^*, Michael Panny, MD⁸^*, Thomas Noesslinger, MD⁸^*, Richard Greil, MD^6,9,10, Panagiotis Samaras, MD¹¹^* and Thomas Pabst, MD¹²

¹3rd Medical Department for Hematology and Oncology, Hanusch Hospital, Vienna, Vienna, Austria
²Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria
³Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland
⁴Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria
⁵Department of Internal Medicine I for Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz Elisabethinen, Linz, Austria
⁶Austrian Group of Medical Tumor Therapy (AGMT) Study Group, Salzburg, Austria
⁷Department of Medical Oncology, University Hospital Bern, Inselspital, Bern, Switzerland
⁸3rd Medical Department for Hematology and Oncology, Hanusch Hospital, Vienna, Austria
⁹Salzburg Cancer Research Institute and Cancer Cluster Salzburg, Salzburg, Austria
¹⁰Paracelsus Medical University, Salzburg, Austria
¹¹Clinic for Hematology & Oncology Hirslanden Zurich, Zürich, Switzerland
¹²University Hospital Bern, Inselspital, Bern, Switzerland

10:00 AM

489

High Efficacy of the PARP Inhibitor Olaparib Combined with High-Dose Chemotherapy and Autologous Stem-Cell Transplant for Refractory Lymphomas

Yago Nieto, MD¹, Benigno C Valdez, PhD¹, Peter F Thall, PhD²^*, Jeremy L. Ramdial, MD¹, Samer A Srour, MD, MS¹, Chitra Hosing, MD¹, Neeraj Saini, MD¹, Amin M Alousi, MD¹, Muzaffar H Qazilbash, MD¹, Uday R Popat, MD¹, Alison Gulbis, PharmD³^*, Terri Lynn Shigle, PharmD³^*, Roland Bassett, MS²^*, Maria Guillermo-Pacheco¹^*, Celina Ledesma¹^*, Paolo Strati, MD⁴, Sairah Ahmed, MD⁴, Raphael Steiner, MD⁴^*, Jason Westin, MD⁴, Ranjit Nair, MD⁴^*, Swaminathan P. Iyer, MD⁴, Richard E Champlin, MD¹, Elizabeth J Shpall, MD¹ and Borje S Andersson, MD, PhD¹

¹Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
³Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX
⁴Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

10:15 AM

490

A Phase 2 Study of Pembrolizumab (MK-3475) after Autologous Stem Cell Transplantation in Patients with T-Cell Non-Hodgkin Lymphoma

Mwanasha H. Merrill, MD¹, Parastoo B. Dahi, MD², Robert A. Redd, MS³^*, Mikaela M. McDonough, BS⁴^*, Yi-Bin Chen, MD, MS⁵, Ann S. LaCasce, MD⁶, David C. Fisher, MD⁴^*, Alex F. Herrera, MD⁷, Caron A. Jacobson, MD⁸, Austin I. Kim, MD⁴, Reid W. Merryman, MD⁹, Oreofe O. Odejide, MD, MPH¹⁰, Samuel Ng, MD, PhD⁴^*, Yago Nieto, MD¹¹, Craig S. Sauter, MD¹²^*, Gunjan L. Shah, MD¹³^*, Jasmine Zain, MD¹⁴, Philippe Armand, MD, PhD⁴^* and Eric D Jacobsen⁸

¹Dana Farber Cancer Institute, boston, MA
²Memorial Sloan Kettering Cancer Center, New York, NY
³Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
⁴Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁵Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA
⁶Division of Hematologic Malignancies, Dana-Farber Cancer Inst., Boston, MA
⁷City of Hope, Duarte, CA
⁸Dana-Farber Cancer Institute, Boston, MA
⁹Brigham and Women's Hospital, Boston, MA
¹⁰Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA
¹¹Department of Stem Cell Transplantation and Cellular Therapy, UT M.D. Anderson Cancer Ctr., Houston, TX
¹²Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland Clinic, Cleveland, OH
¹³Department of Medicine, Adult Bone Marrow Transplant Service, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY
¹⁴City of Hope Comprehensive Cancer Center, Duarte, CA

10:30 AM

491

Phase II Study of PD-1 Blockade Following Fludarabine/Melphalan-Based Autologous Transplantation for Acute Myeloid Leukemia Patients Ineligible for Allogeneic Transplant

Scott R. Solomon, MD¹, Melhem Solh, MD¹, Lawrence E. Morris Jr., MD¹^*, H. Kent Holland, MD¹, Lizamarie Bachier-Rodriguez, MD¹^*, Xu Zhang, PhD²^*, Caitlin Guzowski¹^*, Katelin C Jackson¹^*, Stacey Brown, CCRP¹^* and Asad Bashey, MD, PhD¹

¹Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA
²Center for Clinical and Transitional Sciences, University of Texas Health Science Center, Houston, TX

10:45 AM

492

Late Morbidity and Mortality after Autologous Blood or Marrow Transplantation (BMT) for Lymphoma in Children, Adolescents and Young Adults – a Report from the BMT Survivor Study (BMTSS)

Anna Sallfors Holmqvist, MD, PhD¹^*, Qingrui Meng, MS²^*, Chen Dai, MS³^*, Lindsey Hageman, MPH²^*, Wendy Landier, PhD, CRNP²^*, Jessica Wu, MPH²^*, Liton F. Francisco, BS²^*, Elizabeth Schlichting, MBA²^*, Nora Balas, MSPH²^*, Alysia Bosworth, BA⁴^*, Hok Sreng Te⁵^*, Ravi Bhatia, MD⁶, Joseph Rosenthal, MD⁷^*, Lennie Wong, PhD⁸^*, Daniel J. Weisdorf, MD⁹, Saro H. Armenian, DO, MPH¹⁰ and Smita Bhatia, MD, MPH²

¹Department of Clinical Sciences, Lund University, Pediatric Oncology and Hematology, Skane University Hospital, Lund, Sweden
²Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL
³Institute for Cancer outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL
⁴Department of Population Sciences, City of Hope, Durate, CA
⁵University of Minnesota, Minneapolis, MN
⁶Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL
⁷Pediatric Hematology/Oncology, City of Hope, Duarte, CA
⁸Department of Population Sciences, City of Hope, Duarte, CA
⁹Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN
¹⁰Department of Pediatrics, City of Hope Comprehensive Cancer Center, Duarte, CA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

731.O1.6 731. Autologous Transplantation: Clinical and Epidemiological: Lymphoma, AML, and Multiple Sclerosis